Michel Roethlisberger

Dr. Michel Roethlisberger

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in World Neurosurgery
Verified
Journal Article
Closed access
JRJonathan Rychen
Jonathan Rychen
DCDavide Croci
Davide Croci
Michel RoethlisbergerMichel Roethlisberger
Michel Roethlisberger
ENErez Nossek
Erez Nossek
MPMatthew Potts
Matthew Potts
DZDaniel W. Zumofen
Daniel W. Zumofen

1 February 2017 in World Neurosurgery
Verified
Journal Article
Closed access
DZDaniel Walter Zumofen
Daniel Walter Zumofen
JRJonathan Rychen
Jonathan Rychen
Michel RoethlisbergerMichel Roethlisberger
Michel Roethlisberger
ETEthan Taub
Ethan Taub
DKDaniel Kalbermatten
Daniel Kalbermatten
LMLuigi Mariani
Luigi Mariani

21 June 2021 in Pituitary
Verified
Journal Article
Closed access
PDF file
SBSven Berkmann
Sven Berkmann
Michel RoethlisbergerMichel Roethlisberger
Michel Roethlisberger
BMBeat Mueller
Beat Mueller
MCMirjam Christ-Crain
Mirjam Christ-Crain
LMLuigi Mariani
Luigi Mariani
FJFreimut Juengling
Freimut Juengling

4 May 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
Michel RoethlisbergerMichel Roethlisberger
Michel Roethlisberger
GMGiusi Moffa
Giusi Moffa
UFUrs Fisch
Urs Fisch
BWBenedikt Wiggli
Benedikt Wiggli
SSStephan Schoen
Stephan Schoen
LMLuigi Mariani
Luigi Mariani
Observational studies have shown that dressings containing chlorhexidine gluconate (CHX) lower the incidence external ventricular drain (EVD)–associated infections (EVDAIs). This prospective, randomized controlled trial (RCT) studies the efficacy of CHX-containing dressings in reducing bacterial colonization. In this RCT, patients aged ≥18 years undergoing emergency EVD placement were randomly given either a CHX-containing or an otherwise identical control dressing at the skin exit wound. The primary end-point was bacterial regrowth in cultured skin swab samples of the EVD exit wound. The secondary end-points were catheters processed by sonication, clinically diagnosed EVDAI and surgical treatment of hydrocephalus. From October 2013 to January 2016, a total of 57 patients were randomized to receive either a CHX or a control dressing (29 and 28 patients, respectively). Cutaneous bacterial regrowth at the EVD exit wound was significantly reduced over time (geometric mean ratio, 0.18; 95% confidence interval, .08–.42; P < .001). The incidence of colonized catheters was lower in the CHX group (5 of 28; 18%) than in the control group (10 of 27; 33%), with less microbial colonization on the subcutaneous portion. The infection rate was 4 of 28 (14%) in the CHX group, compared with 7 of 27 (26%) in the control group, with a substantially lower hydrocephalus treatment rate (7 of 28 [25%] vs 14 of 27 [52%], respectively). Our data support the use of CHX dressings to reduce EVD exit site contamination, potentially reducing EVDAIs and permanent cerebrospinal fluid diversion procedures for hydrocephalus. NCT02078830.

4 January 2023 in Neurosurgery
Verified
Journal Article
Open access
JGJohannes Goldberg
Johannes Goldberg
WZWerner J. Z'Graggen
Werner J. Z'Graggen
MHMartin Hlavica
Martin Hlavica
MBMattia Branca
Mattia Branca
SMSerge Marbacher
Serge Marbacher
CFChristian Fung
Christian Fung
BACKGROUND: Poor-grade aneurysmal subarachnoid hemorrhage (aSAH) is associated with high mortality and poor disability outcome. Data on quality of life (QoL) among survivors are scarce because patients with poor-grade aSAH are underrepresented in clinical studies reporting on QoL after aSAH. OBJECTIVE: To provide prospective QoL data on survivors of poor-grade aSAH to aid clinical decision making and counseling of relatives. METHODS: The herniation World Federation of Neurosurgical Societies scale study was a prospective observational multicenter study in patients with poor-grade (World Federation of Neurosurgical Societies grades 4 & 5) aSAH. We collected data during a structured telephone interview 6 and 12 months after ictus. QoL was measured using the EuroQoL - 5 Dimensions - 3 Levels (EQ-5D-3L) questionnaire, with 0 representing a health state equivalent to death and 1 to perfect health. Disability outcome for favorable and unfavorable outcomes was measured with the modified Rankin Scale. RESULTS: Two hundred-fifty patients were enrolled, of whom 237 were included in the analysis after 6 months and 223 after 12 months. After 6 months, 118 (49.8%) patients were alive, and after 12 months, 104 (46.6%) patients were alive. Of those, 95 (80.5%) and 89 (85.6%) reached a favorable outcome with mean EQ-5D-3L index values of 0.85 (±0.18) and 0.86 (±0.18). After 6 and 12 months, 23 (19.5%) and 15 (14.4%) of those alive had an unfavorable outcome with mean EQ-5D-3L index values of 0.27 (±0.25) and 0.19 (±0.14). CONCLUSION: Despite high initial mortality, the proportion of poor-grade aSAH survivors with good QoL is reasonably large. Only a minority of survivors reports poor QoL and requires permanent care.

3 August 2018 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
Michel RoethlisbergerMichel Roethlisberger
Michel Roethlisberger
RARita Achermann
Rita Achermann
SBSchatlo Bawarjan
Schatlo Bawarjan
MSMartin N Stienen
Martin N Stienen
CFChristian Fung
Christian Fung
SGSwiss SOS group
Swiss SOS group
BACKGROUND: One-third of patients with aneurysmal subarachnoid hemorrhage (aSAH) have multiple intracranial aneurysms (MIA). OBJECTIVE: To determine the predictors of outcome in aSAH patients with MIA compared to aSAH patients with a single intracranial aneurysm (SIA). METHODS: The Swiss Study of Subarachnoid Hemorrhage dataset 2009-2014 was used to evaluate outcome in aSAH patients with MIA compared to patients with SIA with the aid of descriptive and multivariate regression analysis. The primary endpoints of this cohort study were presence of new stroke on computed tomography (CT) after aneurysm treatment, and presence of stroke on CT prior to discharge. The secondary endpoints were the clinical and the functional status, and the overall mortality at discharge and at 1 yr. RESULTS: Among 1689 consecutive patients, 467 had MIA (prevalence: 26.4%). The incidence of stroke was higher in the MIA than in the SIA group, both after aneurysm treatment (19.3% vs 15.1%) and at discharge (24% vs 21.4%). However, the 95% confidence interval (CI) for the corresponding odds ratio (OR) in our multivariate model included 1, indicating that the detected trends did not reach statistical significance. As for the secondary endpoints, aneurysm multiplicity was found to be an independent, statistically significant predictor for occurrence of a new focal neurological deficit between admission and discharge (OR 1.40, 95% CI 1.08-1.81). Yet, the MIA and SIA groups did not differ in terms of either functional outcome or overall survival. CONCLUSION: aSAH patients with MIA have a higher short-term morbidity than patients with SIA. This excess morbidity does not worsen the functional outcome or lower overall survival.